Somatostatin and α2-adrenergic agonists selectively inhibit vasopressin-induced cyclic AMP accumulation in MDCK cells  by Friedlander, Gerard & Amiel, Claude
Volume 198, number 1 FEBS 3495 March 1986 
S~matostatin and a,-adrenergic agonists selectively inhibit 
vasopressin-i~~~ce~ cyclic AMP accumulation 
in MDCK cells 
Gerard Friedlander and Claude Amiel 
INSERM U.251 and RPpartement de Physiologic, Fact& Xavier &chat, 16, rue Henri Huchard, 
F-75018 Paris, France 
Received 17 January 1986 
The etfect of somatostatin and qadrenergic agonists on cyclic AMP accumulation was examined in MDCK 
cells, grown in defined medium. These hormones inhibited vasopressin-indu~d cyclic AMP formation, with- 
out affecting either the basal or the glucagon- and prostaglandin E,-stimulated level. Pretreating the cells 
with pertussis toxin, or incubating them with MnCl, at a low concentration reversed the effect of somato- 
statin and q-agonists. These results suggest hat somatostatin and norepinephrine could selectively modu- 
late the renal effect of vasopressin. via the inhibitory regulatory subunit (N,) of adenylate cyclase. 
(MDCK cell) cyclic AMP Vasopressin 
1. INTRODUCTION 
Among the properties of the renal distal tubule 
epithelium, retained by the MDCK cell line, is hor- 
monal responsiveness to vasopressin, glucagon and 
prostaglandin E2 which stimulate intracellular 
cyclic AMP accumulation in these cells [ 1,2]. Fur- 
thermore, SRIF has been reported to inhibit 
vasopressin-induced cyclic AMP accumulation in 
the distal parts of the rat nephron [3]. A similar in- 
teraction between vasopressin and cuz-adrenergic 
agonists was recently described in the rat collecting 
tubule [4,5]. 
The purpose of this study was to examine, in 
MDCK cells, the possible inhibition by SRIF and 
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a2-adrenergic agonists of vasopressin-, glucagon- 
and prostaglandin E2-stimulated cyclic AMP for- 
mation, and to define further the mechanism of 
such an inhibition. The results showed that 
vasopressin-induced cyclic AMP generation was 
selectively inhibited by SRIF and norepinephrine 
whereas the response to glucagon and prostaglan- 
din Ez was unaffected. This inhibition occurred 
likely through stimulation of the Ni subunit of 
adenylate cyclase. 
2. MATERIALS AND METHODS 
Arginine-vasopressin, prostaglandin Ez, L- 
norepinephrine bitartrate salt, DL-propranolol 
HCI, IBMX, BSA and indomethacin were from 
Sigma (St. Louis, MO), glucagon from Novo 
(Paris), SRIF from Clin-Midy (Paris) and 
clonidine NC1 from Boehringer Ingelheim (FRG). 
Cell culture media were from Flow Labs 
(England), plastic ware from Falcon Labware (Ox- 
nard, CA) and carrier-free Na”‘I from Amersham 
(England). IAP was a generous gift from Dr F. 
Maigrt (Institut Pasteur, Paris). 
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2.2. methods 
MDCK cells (passages 69-74) were grown in 
serum-free medium f6] and subcultured once week- 
ly. For cyclic AMP determination, MDCK cells 
were grown to confluence (3-4 days; =5 x 10’ 
cells/well) in 24-well culture dishes. All steps were 
performed at 37°C. The cells were washed twice 
with 1 ml buffer (HBSS, 1 mg/ml BSA, 20 mM 
Hepes), preincubated for 10 min in buffer contain- 
ing 0.5 mM IBMX, and incubated for 5 min in 
fresh buffer containing hormones and drugs to be 
tested. Cyclic AMP was extracted as in 141 and 
measured, after acetylation [7], by radioim- 
munoassay [S,9]. Results are expressed as pmol 
cyclic AMP/culture well, each well containing 
55-60 gg cell protein [lo]. 
3. RESULTS 
3.1. Effects of SRIF on hormone-induced cyclic 
AMP accumulation 
The hormonal responsiveness of MDCK cells is 
shown in fig-l. 1 FM vasopressin, glucagon and 
prostaglandin EZ induced a 6-, 8- and 11-fold in- 
CAMP 
( pmol/wellI 
i 
* 
1 
AVP 
AYP 
CLU cLu 
5 
* 
1 
i 
PCE2 IS0 1 
Fig.1. Effect of 1 PM vasopressin (AVP), glucagon 
(GLU), prostaglandin Ez (PGE2) and isoproterenol 
(ISO) on intracellular cyclic AMP (CAMP) 
accumulation. * Significantly different from the basal 
value, p < 0.01. 5~ Significantly different from the value 
obtained with AVP or glucagon alone, p < 0.01. 
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Fig.2. Effect of 20yM SRIF on basal and 1 pM 
vasopressin- (AVP), glucagon- (GLU) and prostaglandin 
E2- (PGE2) stimulated intracelluiar cyclic AMP (CAMP) 
accumulation. * Significantly different from the value 
obtained without SRIF, p < 0.01. 
crease in cyclic AMP content, respectively, 
whereas isoproterenol induced no significant 
stimulation. Vasopressin and glucagon had ad- 
ditive effects. SRIF (fig.2) affected neither the 
basal cyclic AMP value (1.8 f 0.3 vs 1.9 + 
0.2 pmol CAMP/well, without and with SRIF, 
respectively; NS) nor glucagon- (9.1 f 0.4 vs 8.5 + 
0.6 pmol/well; NS) or prostaglandin-Ez- (8.1 + 0.4 
vs 8.4 f 0.7 pmolfwell; NS) stimulated cyclic 
AMP accumulation, whereas it signific~tly re- 
duced the vasopressin-induced cyclic AMP genera- 
tion (9.4 + 0.4 vs 5.9 t 0.6 pmol/well; p < 0.01) 
in a dose-dependent manner (fig.3). 
3.2. Effect of az-agonists on hormone-induced 
cyclic AMP accumulation (fig.41 
10~M norepinephrine did not affect in- 
tracellular cyclic AMP content under basal condi- 
tions (1.7 f 0.2 vs 1.6 +_ 0.2 pmol/well, without 
and with norepinephrine, respectively; NS), and 
after glucagon or prostaglandin EZ stimulation. In 
contrast, norepinephrine dose-dependently in- 
hibited v~opressin-induct cyclic AMP accumula- 
tion. A similar pattern was observed with the 
a2-agonist clonidine. 
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Fig.4, Effect of norepinephrine (left) and &&dine 
(right) on SO nM vasopressin- (AVP), gtucagon- (GLU), 
and prostaglandin EZ (PGEz) induced cyclic AMP 
@AMP) accumulation. Con&of vatues (without 
norepinephr~ne or clonidine) were 8.7 f 0.4, 7.5 I 0.3 
and 7.3 f 0.3 pmol/weli for vasopressin-, glucagon- and 
prostagi~din Ez-stimufated cyclic AMP accumulation, 
respectively (means f SE, n = 6). The experiments with 
norepinephrine were performed in the presence of 10 PM 
propranolol, to block a possible P-adrenergic 
stimulation of cyclic AMP formation. From 0.1 pM 
norepinephrine and ctonidine, values were different 
from the control vahte, p < 0.05. 
Fig.3, Effect of increasing concentrations of SRIF on 
50 nM vasopressin- (AVP) stimulated cyclic AMP 
(CAMP) a~~umu~atjon. The control value (w~~out 
SRIF) was 8.5 k 0.3 pmol/we~l (mean 4 SE, n = 6). 
From 1 pM SRIF, values were significantly different 
from the contro1 vahre, p < 0.05, 
TabIe I 
18 h preinc~bation of MDCK cells with 
250 ng/ml IAP reversed the inhibitory action of 
SRIF and nor~pi~ephrin~ on v~opre~~in~i~d~c~d 
cyclic AMP accumulation (table I). Incubation of 
Effect of pertussis toxia (IAP) on inhibition of intracellular cyclic AMP 
accumulation (pmol/wei~) induced by SRIF and nor~pinephrine 
IAP Control + SRIF 
(20 PM) 
+ norepinephrine 
(I PM), 
propranoI0~ 
(IO&Q 
Basal 1.8 + 0.23 I.8 + 0.14 I.7 f 0.12 
+ 2.3 + 0.64 2.5 + 0.71 2.1 zt 0.42 
Vasopressin 12.8 t 1.39 8.9 + 0.64’ 8.3 -f 0.26b 
(50 nM) + 11.6 + 0.59 IO.8 it 0.37’ 9.8 f 0.4@ 
a,b Signifi~tly different from the control value, p < 0.05 and 0.02, respectively 
(rz = 6) 
’ Significantly different from the homologous values without IAP, p < 0.05 (n = 
61 
MDCK cells were pre~ncubated for 18 h with 250 nglml IAP 
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Table 2 
Effect of MnCl2 (1 mM) on inhibition of intracellular cyclic AMP accumulation 
(pmol/well) induced by SRIF and clonidine 
March 1986 
MnCl2 Control -I- SRIF + clonidine 
(20 PM) (1 FM) 
Basal 1.4 f 0.12 1.3 & 0.10 1.4 f 0.13 
+ 1.6 f 0.13 1.4 + 0.31 1.7 f 0.10 
Vasopressin 17.6 f 0.39 11.0 f 0.3ga 11.9 f 0.20” 
(50 nM) + 24.2 + 1.50b 23.4 f 1.20b 21.5 + 2.40b 
a Significantly different from the control value, p < 0.01 (n = 6) 
b Significantly different from the homologous values without MnClz, p < 0.01 (n = 
6) 
10pM indomethacin was added to the medium during preincubation and 
incubation 
the cells with 1 mM MnCl2 led to a significant 
enhancement of vasopressin-induced cyclic AMP 
formation, and an almost complete reversion of 
the inhibitory effect of SRIF and clonidine (table 
2). 
4. DISCUSSION 
The results showed that SRIF and arz-adrenergic 
agonists inhibit vasopressin-induced, but not 
glucagon- or prostaglandin E2-induced, cyclic 
AMP accumulation in MDCK cells, via stimula- 
tion of Nip the inhibitory, regulatory component of 
adenylate cyclase. 
In MDCK cells, (or- and fl-adrenergic-binding 
sites have been identified [ 111. Our results, 
however, strongly suggest an cY2-receptor-mediated 
effect of catecholamines which could account, at 
least partly, for the antagonism between 
norepinephrine and vasopressin documented in 
vivo [ 12,131 and in vitro [ 141. Ceilular heterogene- 
ity in MDCK cells was indicated by the additive ef- 
fects of vasopressin and glucagon on cyclic AMP 
accumulation (fig.l), and likely accounted for the 
selective effect of SRIF and norepinephrine on 
vasopressin-induced, but not glucagon- or pros- 
taglandin Ez-induced, cyclic AMP generation. 
In other systems, inhibition of cyclic AMP ac- 
cumulation by SRIF and norepinephrine was 
ascribed to a stimulation of Ni and could be re- 
versed by IAP [15,16], which specifically inac- 
tivates Ni [17]. Our results (table 1) lead to a 
similar conclusion in MDCK cells. The absence of 
the reported increase by IAP [17] of hormone- 
stimulated cyclic AMP production might be the 
consequence of concomitant inhibition by IAP of 
prostaglandin synthesis fl8,19]. Indeed, in the 
presence of indomethacin, manganese, which is 
known to inhibit selectively Ni 1201 at low concen- 
trations, enhanced the effect of vasopressin and 
blunted that of SRIF and clonidine. 
As far as SRIF is concerned, its synthesis in toad 
urinary bladder and renal tubule [21] and rat 
glomeruli [22,23] is consistent with its role as a 
locally produced, modulating agent of vasopressin 
action, as evidenced in vivo [3,24] and in vitro 
[3,25,26] in both the amphibian bladder and the 
mammalian kidney. 
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